Dragotti & Associati wins another “quetiapine case” in Sandoz vs. AstraZeneca

With a decision issued on May 15, 2015, the Specialized Section of the Turin Court confirmed that the Italian portion of AstraZeneca’s European patent EP907364B1 is invalid since it lacks inventive step.

Sandoz was represented by Gianpaolo Di Santo, from the law firm Pavia & Ansaldo, who was assisted by the technical experts Roberto Pistolesi (Dragotti & Associati) and Prof. Achile Patrizio Caputi (University of Messina).

This decision is in line with the orders issued by the same Court on January 13 and April 1, 2015, where a request for preliminary injunctions filed by AstraZeneca against Accord, which was also assisted by Pavia & Ansaldo and Dragotti & Associati, was rejected on the same grounds.

See also:

http://www.toplegal.it/news/2015/06/03/15651/sandoz-con-pavia-e-ansaldo-ottiene-nullita-di-un-brevetto-astrazeneca